Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025)
Inhibikase Therapeutics' (IKT) quarterly Total Debt came in at $37944.0 in Q2 2025, down 75.07% year-on-year from $152224.0 in Q2 2024, and down 49.25% on a QoQ basis from $74772.0 in Q1 2025.
Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of Total Debt data on file, last reported at $37944.0 in Q2 2025.
- On a quarterly basis, Total Debt fell 75.07% year-over-year to $37944.0 in Q2 2025; TTM through Jun 2025 was $37944.0, a 75.07% decrease from a year earlier, with the FY2024 full-year figure at $110517.0, down 79.22% from the prior year.
- Total Debt for Q2 2025 stood at $37944.0, down from $74772.0 in the prior quarter.
- Over the last five years, Total Debt for IKT reached as high as $1.2 million in Q1 2021 and fell as low as $37944.0 in Q2 2025.
- Historically, Total Debt has averaged $245133.9 across 5 years, with a median of $147966.0 in 2023.
- Across the five-year window, Total Debt surged 264.71% in 2023 and plunged 79.22% in 2024, its largest moves.
- Year by year, Total Debt stood at $248911.0 in 2021, then sank by 41.41% to $145836.0 in 2022, then jumped by 264.71% to $531879.0 in 2023, then plunged by 79.22% to $110517.0 in 2024, then plunged by 65.67% to $37944.0 in 2025.
- Per Business Quant data, the three most recent Total Debt figures were $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 37,944.00 |
| Mar 31, 2025 | 74,772.00 |
| Dec 31, 2024 | 110,517.00 |
| Sep 30, 2024 | 145,210.00 |
| Jun 30, 2024 | 152,224.00 |
| Mar 31, 2024 | 151,159.00 |
| Dec 31, 2023 | 531,879.00 |
| Sep 30, 2023 | 149,030.00 |
| Jun 30, 2023 | 147,966.00 |
| Mar 31, 2023 | 146,901.00 |
| Dec 31, 2022 | 145,836.00 |
| Sep 30, 2022 | 142,048.00 |
| Sep 30, 2021 | 248,911.00 |
| Jun 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 1.24 Mn |
| Dec 31, 2020 | 276,461.00 |